Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Eltrombopag Plus G-CSF for Peripheral Blood Stem Cell Mobilization: Interim Analysis of a Single Arm, Phase 2 Trial

Ta-Chuan Yu, Tai-Chung Huang, Shang-Ju Wu

Blood (2024) 144 (Supplement 1): 2092.

https://doi.org/10.1182/blood-2024-204224

Published: 2024

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Emmanuel Bachy, Peter Trask, Franck Morschhauser, Paolo Corradini, Shang-Ju Wu, Nancy L. Bartlett, Estefania Mulvihill, Fabiola Bene Tchaleu, Linda Lundberg, Carmelo Carlo-Stella

Blood (2024) 144 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2024-194337

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study

Emmanuel Bachy, Tae Min Kim, Shang-Ju Wu, Jan Walewski, Jingxian Cai, Nickolas Sophos, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, H. Miles Prince

Blood (2024) 144 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2024-200150

Published: 2024

Journal Articles

Characteristics and Long-Term Efficacy of 25 Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab or Ravulizumab in Taiwan

Hsing-Yu Lin, Yu-Wen Chen, Ta-Chuan Yu, Feng-Ming Tien, Chien-Chin Lin, Sheng-Chieh Chou, Shang-Ju Wu, Bor-Sheng Ko, Yung-Li Yang, Ming Yao, Woei Tsay, Hwei-Fang Tien, Hsin-An Hou, Wen-Chien Chou

Blood (2024) 144 (Supplement 1): 5672.

https://doi.org/10.1182/blood-2024-199918

Published: 2024

Journal Articles

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Blood (2024) 144 (Supplement 1): 213.

https://doi.org/10.1182/blood-2024-194827

Published: 2024

Journal Articles

Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

Chun-Kai Liao, Chia-Jen Liu, Tran-Der Tan, Ming-Chung Wang, Ya-Ting Hsu, Hung-Lin Liu, Shang-Ju Wu, Hsueh-Ju Lu, Jeng-Shiun Du, Wan-Jhen Gao, Cheng-Chih Tsai

Blood (2024) 144 (Supplement 1): 5137.

https://doi.org/10.1182/blood-2024-201386

Published: 2024

Journal Articles

A Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Patterns, and Resource Utilization for Patients with Chronic Lymphocytic Leukemia: CREEK Study

Ahmad Alhuraiji, Ayman Alhejazi, Mohamed Samra, Bhausaheb Bagal, Miguel Arturo Pavlovsky, Macarena Roa, Shang-Ju Wu, Efreen H Montano Figueroa, Veena Selvaratnam, Chee-Yen Lin, Pushpalata K, Akemi Ishikawa, Francisco Gonzalez Hernandez

Blood (2023) 142 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2023-189992

Published: 2023

Journal Articles

PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Pankit Vachhani, Jana Baskar, Brett Charlton, Stanley Cheung, Wolfgang Jarolimek, Sung-Eun Lee, Peter Tan, Anne Marie Watson, Shang-Ju Wu

Blood (2023) 142 (Supplement 1): 625.

https://doi.org/10.1182/blood-2023-181383

Published: 2023

Journal Articles

Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Yu-Hua Fu, Shang-Ju Wu, Elise Chia-Hui Tan, Chi-Chuan Wang, Kibum Kim, Wen-Chien Chou, Fang-Ju Lin

Blood (2022) 140 (Supplement 1): 10808–10809.

https://doi.org/10.1182/blood-2022-162980

Published: 2022

Journal Articles

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Blood (2021) 138 (Supplement 1): 128.

https://doi.org/10.1182/blood-2021-148778

Published: 2021

Journal Articles

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Cheng-Hong Tsai, MD MSc, Feng Ming Tien, MD MSc, Hsin-An Hou, MD PhD, Jia-Hau Liu, MD, Shang-Ju Wu, MD PhD, Yu-Wen Wang, MSc., Chien-Chin Lin, MD, Bor-Sheng Ko, MD PhD, Wen-Chien Chou, MD PhD, Yun-Chu Lin, MD, Chieh-Lung Cheng, MD, Li-Chun Lu, MD PhD, Sung-Hsin Kuo, MD PhD, Ruey-Long Hong, MD PhD, Tai-Chung Huang, MD PhD, Ming Yao, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-138481

Published: 2020

Journal Articles

Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3 -ITD Patients

Blood (2018) 132 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2018-99-114315

Published: 2018

Journal Articles

The Implications of Endoplasmic Reticulum Stress Response in the Prognosis and Pathogenesis of Myelodysplastic Syndrome

Ming-En Lin, MD, Wen-Chien Chou, MD, PhD, Yu-Chiao Chiu, PhD, Mei-Hsuan Tseng, M.Sc., Ming-Chih Liu, Chia-Wen Liu, Jih-Luh Tang, MD,PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Chien-Yuan Chen, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Hsin-An Hou, MD, PhD, Shang-Ju Wu, MD, PhD, Chien-Ting Lin, MD, Woei Tsai, MD, PhD, Yidong Chen, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 4249.

https://doi.org/10.1182/blood.V130.Suppl_1.4249.4249

Published: 2017

Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim

Blood (2017) 130 (Supplement 1): 4128.

https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128

Published: 2017

Journal Articles

Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia

Cheng-Hong Tsai, MD, M.Sc., Hsin-An Hou, MD, PhD, Jih-Luh Tang, MD,PhD, Yuan-Yeh Kuo, PhD, Yu-Chiao Chiu, PhD, Chien-Chin Lin, MD, Liang-In Lin, PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Chien-Yuan Chen, MD, PhD, Woei Tsai, MD, PhD, Wen-Chien Chou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 2582.

https://doi.org/10.1182/blood.V130.Suppl_1.2582.2582

Published: 2017

Journal Articles

The Clinical and Biological Implications of Aberrant Alternative Splicing in Patients with De Novo, Non-M3 Acute Myeloid Leukemia

Chiu Po-Ju, MD, Yi-Tsung Yang, Yu-Chiao Chiu, PhD, Hsin-An Hou, MD, PhD, Jih-Luh Tang, MD,PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Woei Tsai, MD, PhD, Yidong Chen, PhD, Wen-Chien Chou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 1382.

https://doi.org/10.1182/blood.V130.Suppl_1.1382.1382

Published: 2017

Journal Articles

The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia

Jui-Che Chen, MD, Cheng-Hong Tsai, MD, M.Sc., Jih-Luh Tang, MD,PhD, Yuan-Yeh Kuo, PhD, Chien-Chin Lin, MD, Mei-Hsuan Tseng, M.Sc., Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, MD, PhD, Bor-Sheng Ko, MD, PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD, PhD, Chien-Yuan Chen, MD, PhD, Woei Tsai, MD, PhD, Wen-Chien Chou, MD, PhD, Hsin-An Hou, MD, PhD, Hwei-Fang Tien, MD, PhD

Blood (2017) 130 (Supplement 1): 1300.

https://doi.org/10.1182/blood.V130.Suppl_1.1300.1300

Published: 2017

Journal Articles

Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome

Yi-Tsung Yang, Wen-Chien Chou, MD PhD, Yu-Chiao Chiu, Hsin-An Hou, MD PhD, Jih-Luh Tang, MD PhD, Ming Yao, MD, Chi-Cheng Li, MD, Shang-Yi Huang, Bor-Sheng Ko, MD PhD, Chien-Yuan Chen, MD PhD, Szu-Chun Hsu, MD, Chien-Ting Lin, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2016) 128 (22): 49.

https://doi.org/10.1182/blood.V128.22.49.49

Published: 2016

Journal Articles

The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL)

Feng-Ming Tien, MD, Hsin-An Hou, MD PhD, Chien-Yuan Chen, MD PhD, Wen-Chien Chou, MD PhD, Chi-Cheng Li, MD, Chien-Ting Lin, MD, Ming Yao, MD, Shang-Yi Huang, MD PhD, Bor-Sheng Ko, MD PhD, Szu-Chun Hsu, MD, Shang-Ju Wu, MD PhD, Woei Tsay, MD PhD, Jih-Luh Tang, MD PhD, Hwei-Fang Tien, MD PhD

Blood (2016) 128 (22): 2860.

https://doi.org/10.1182/blood.V128.22.2860.2860

Published: 2016

NARROW

Eltrombopag Plus G-CSF for Peripheral Blood Stem Cell Mobilization: Interim Analysis of a Single Arm, Phase 2 Trial

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Primary Results of the Health-Related Quality of Life (HRQoL) and Tolerability Assessments from the Phase I/II NP30179 Study of Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Efficacy and Safety of Odronextamab in Rare Subtypes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL): Data from a Dedicated Cohort of Other B-NHLs in the ELM-2 Study

Characteristics and Long-Term Efficacy of 25 Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab or Ravulizumab in Taiwan

Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia

Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study

A Multicenter Retrospective Study to Understand the Clinical Characteristics, Treatment Patterns, and Resource Utilization for Patients with Chronic Lymphocytic Leukemia: CREEK Study

PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Polatuzumab Vedotin-Based Salvage Chemotherapy in the Third-Line or Above Treatment for Diffuse Large B-Cell Lymphoma

Re-Examination of 2017 ELN Risk Classification By a Cohort of 739 De Novo aml Patients in Taiwan: Co-Occurring Poor-Risk Mutations May Further Predict Outcome in FLT3 -ITD Patients

The Implications of Endoplasmic Reticulum Stress Response in the Prognosis and Pathogenesis of Myelodysplastic Syndrome

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Prognostic Impacts and Dynamic Changes of Cohesin Complex Gene Mutations in De Novo Acute Myeloid Leukemia

The Clinical and Biological Implications of Aberrant Alternative Splicing in Patients with De Novo, Non-M3 Acute Myeloid Leukemia

The Clinical Implication and Prognostic Impact of Dynamic Molecular Evolution in Acute Myeloid Leukemia

Aberrant Patterns of Alternative Splicing Are Frequent Events and Harbor Prognostic Significance in Patients with Myelodysplastic Syndrome

The Clinical Characteristics, Genetic Alterations and Prognostic Significance of De Novo Acute Myeloid Leukemia (AML) with Hyperleukocytosis (HL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only